Get the Stockscreener App
0.8139
0.89%
-0.0073
After Hours:
.84
0.0261
+3.21%
Onconetix Inc stock is traded at $0.8139, with a volume of 91,065.
It is down -0.89% in the last 24 hours and down -16.65% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
See More
Previous Close:
$0.8212
Open:
$0.84
24h Volume:
91,065
Relative Volume:
0.11
Market Cap:
$3.00M
Revenue:
$735.20K
Net Income/Loss:
$-9.70M
P/E Ratio:
-0.00187
EPS:
-435.729
Net Cash Flow:
$-9.80M
1W Performance:
-18.61%
1M Performance:
-16.65%
6M Performance:
-98.93%
1Y Performance:
-99.61%
1-Day Range:
$0.81
$0.88
1-Week Range:
$0.7822
$0.9999
52-Week Range:
$0.711
$229.50
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
0.8139 | 3.03M | 735.20K | -9.70M | -9.80M | -435.73 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Onconetix Inc Stock (ONCO) Latest News
Onconetix (ONCO) 13G: Keystone Capital reports 6.1% beneficial stake - Stock Titan
Onconetix Inc (ONCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Onconetix Inc|Price:0.821|Chg%:+0.032 - TradingKey
TradingKey - TradingKey
Onconetix Inc (ONCO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ONCO|Onconetix Inc|Price:0.821|Chg%:+0.032 - TradingKey
Onconetix Inc (ONCO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ONCO Stock Price, Quote & Chart - ChartMill
Onconetix Inc Revenue Breakdown – FWB:J4T - TradingView
Onconetix Inc (ONCO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Realbotix has two separate businesses: humanoid robots and adult wellness - Stock Titan
Why Is Onco Micro-Cap Stock Surging 50% In Premarket? - Stocktwits
This New York School Is Becoming a Humanoid Robot Company's Biggest Test. There's Just 1 Problem - inc.com
Onconetix (ONCO) stock surges over 23% overnight: Why is it moving? - MSN
Onconetix Inc. (ONCO) Edges Higher but Faces Key Resistance Near $0.83Weak Sell Signals - dars.gov.et
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation - The Manila Times
Onconetix (ONCO) ties Realbotix to Bloom pilot deploying humanoid care robots in UK - Stock Titan
Realbotix robots head to UK care homes in pilot to fight loneliness - Stock Titan
Onconetix Inc. (ONCO) Q1 2025 Earnings: Positive EPS Surprise Amidst Steep Stock DeclineEPS Guidance Update - Bölüm Sonu Canavarı
ONCO Q1 2025 Earnings: Positive EPS Reported Amid Revenue Absence and Stock DeclineMargin Guidance - DonanımHaber
ONCOOnconetix Inc Forecast, Target Price - Finviz
Price to sales forward of Onconetix, Inc. – NASDAQ:ONCO - TradingView
Price to book forward of Onconetix, Inc. – NASDAQ:ONCO - TradingView
Enterprise value to EBITDA forward of Onconetix, Inc. – NASDAQ:ONCO - TradingView
Onconetix Inc. (ONCO) Q1 2025 Earnings: Positive EPS Reported Amid Revenue Gap, Stock DeclinesFinancial Summary - dars.gov.et
Enterprise value to revenue forward of Onconetix, Inc. – NASDAQ:ONCO - TradingView
Onconetix, Inc. (ONCO) Stock Price, News, Quote & History - Yahoo Finance
Onconetix Inc (ONCO) Institutional Confidence - TradingKey
Onconetix Inc (ONCO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onconetix Announces Realbotix Optio and M-Series Humanoid Robot Pilot at Salamanca City Central School District - Quiver Quantitative
Onconetix (ONCO) agrees to buy Realbotix; Optio robot pilot to reach ~500 students - Stock Titan
A robot and AI tutor are headed to a New York school district - Stock Titan
Onconetix Inc. (ONCO) Holds Near Support with Modest GainsIchimoku Kumo Twist - dars.gov.et
Onconetix Inc. (ONCO) Slides 5% as Selling Pressure Persists Near Key SupportShort Setup Alerts - dars.gov.et
Onconetix Inc. (ONCO) Q1 2025 Earnings: Positive EPS Surprise Amid Zero RevenueEarnings Call Transcript - DonanımHaber
Onconetix Inc (ONCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onconetix Inc (ONCO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Onconetix Inc (ONCO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Onconetix (NASDAQ: ONCO) registers 100M shares; Keystone ELOC could deliver $25M - Stock Titan
[EFFECT] Onconetix, Inc. SEC Filing - Stock Titan
Onconetix Plans Reverse Stock Split to Bolster Share Price - timothysykes.com
Onconetix (ONCO) Surges 6.86%: Key Levels and Potential TrajectoryBreakout Stock Alerts - dars.gov.et
ONCO News | ONCONETIX INC (NASDAQ:ONCO) - ChartMill
ONCO Q1 2025 Earnings: Positive EPS Amid Zero Revenue Signals Potential Non-Recurring GainsInterim Report - DonanımHaber
Onconetix Company Profile & Introduction - Moomoo
OnconetixRegisters Up To 100 Million Shares For Resale By Keystone Capital PartnersSEC Filing - TradingView
Onconetix (ONCO) files S-1 for 100M-share Keystone equity line amid going-concern risks - Stock Titan
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):